The global general purpose wipe market is anticipated to grow significantly at a CAGR of 5.6% over the forecast period (2022-2028). The global general purpose wipes market growth is majorly driven by the introduction of new products by prominent players operating in the market growth. In addition,   in February 2022, Essity maker of the Tork brand, has acquired Legacy Converting, Inc., this acquisition will strengthen the Tork portfolio, and provide significant benefit to Essity’s customers, by offering surface cleaning disinfected products.

The global market for animal health products is expected to grow at a significant CAGR of 4.0 % during the forecast period. Among the product segment, the pharmaceutical segment is anticipated to dominate the animal health product market owing to the continuing improvements in veterinary pharmaceuticals. Anti-inflammatory medications, parasiticides, antibiotics, and other pharmaceuticals are among the most common. The growing popularity of companion animals has accelerated the introduction of medications to help people live longer. 

The global rare disease drug market is anticipated to grow at a significant CAGR of 11.4% during the forecast period. The speeding up in the R&D to meet the demand for effective treatment of uncommon conditions such as deadly familial insomnia and rare cardiovascular disorders is one of the prime factors affecting and driving the market. Several research laboratories are concentrating on R&D along with various pharmaceutical companies are doing larger outcome studies for standard medicines. Furthermore, the diagnosis and treatment of rare diseases are the essential driving factors prevailing in the global market.

The global myoglobin market is anticipated to grow at a considerable CAGR of 4.4% during the forecast period (2022-2028). The continual launch of novel myoglobin reagents to improve myoglobin testing is expected to propel the global myoglobin market to new heights in the forecast future. For instance, in November 2021, F. Hoffmann-La Roche Ltd., had introduced the Cobas 5800, a molecular diagnostics system designed and made to improve patient care by increasing access to testing. The Roche's Molecular Cobas 5800 System is a small new addition to the Roche Molecular portfolio that offers efficiency, simplicity, and prompt results to laboratories of all sizes, allowing doctors to swiftly determine the finest treatment plans for their patients. 

The global impetigo drug market is anticipated to grow at a considerable CAGR of 7.1% during the forecast period (2022-2028).  The key factors driving the growth of the impetigo drug market are an increase in infectious diseases, along with an increase in hospital-acquired infections. For instance, the information provided by the University of Oxford highlighted the fact that more than 1.2 million people died in 2019 as a direct result of antibiotic-resistant bacterial infections. Moreover, according to National Center for Biotechnology Information (NCBI), in August 2021, impetigo is responsible for about 10% of all skin issues in children. 

The global market for glial cell line-derived neurotrophic factors is expected to expand at a rapid pace (2022-2028). The rising incidence of Parkinson's disease (PD) throughout the world is one of the primary reasons driving the market's rise. According to the Parkinson Foundation, almost one million persons in the US suffer with Parkinson's disease, with the number expected to increase to 1.2 million by 2030. Furthermore, approximately 60,000 Americans are diagnosed with Parkinson's disease each year, and the disease affects over 10 million people globally. Parkinson's disease increases with age; nevertheless, only around 4% of those diagnosed with Parkinson's disease are under the age of 50.

The global cyclobenzaprine market is anticipated to grow at a considerable CAGR of 4.2% during the forecast period (2022-2028). The growing senior population is expected to drive market expansion throughout the forecast period.  Cyclobenzaprine is used to treat skeletal muscle discomfort and damage in combination with rest and physical therapy. It supports reducing pain, stiffness, and discomfort associated with muscle strains, sprains, and injuries. The senior population is more prone to musculoskeletal issues. This is due to their muscles weakening, which results in pains, cramps, and other muscle-related issues. People utilize prescription and over-the-counter (OTC) medications, including muscle relaxants, to treat these age-related musculoskeletal disorders.

The global eye health supplements market is anticipated to grow at a considerable CAGR of around 5.5% during the forecast period (2022-2028). Increasing launches of eye health supplements to fulfill the demand of individuals suffering from vision impairment across the globe is driving the market growth and this in turn further drives the sales of eye health supplements. For instance, in July 2019, Bausch + Lomb launched Ocuvite Eye Performance vitamins, a nutritional supplement.

The global axial spondyloarthritis drug market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period (2022-2028). The market is primarily driven by favorable conditions for pharmaceutical producers and the attention of various government agencies on enhancing the current healthcare infrastructure. These will lead to a rise in global demand for various drugs for treatment options for axial spondyloarthritis in the near future. Additionally, significant investment in research and development, favorable reimbursement circumstances, and rising incidences and prevalence may all contribute to market growth. 

The global anaplastic astrocytoma drug market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period (2022-2028). Globally, research and development for better patient treatment for brain disorders are speeding up. The number of pipeline drugs for brain tumor medications has increased as a result of innovative research leading to combination therapies with novel or existing therapeutic molecules. Additionally, in January 2020, the National Brain Tumor Society (NBTS) announced a multi-year funding commitment of atleast $200,000 to support an upcoming phase II clinical trial of ONC201, an investigational therapeutic.